Literature DB >> 7351605

Long-term low-dose prostaglandin E1 administration.

P Pitlick, J W French, A Maze, K J Kimble, R L Ariagno, B A Reitz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351605     DOI: 10.1016/s0022-3476(80)80838-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

1.  Anaesthetic managements for conjoined twins with complex cardiac anomalies.

Authors:  T L Chen; C J Lin; H S Lai; W J Chen; C C Chao; C C Liu
Journal:  Can J Anaesth       Date:  1996-11       Impact factor: 5.063

2.  Use of prostaglandin E2 in management of transposition of great arteries before balloon atrial septostomy.

Authors:  A Beitzke; C H Suppan
Journal:  Br Heart J       Date:  1983-04

3.  Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.

Authors:  B D Thanopoulos; A Andreou; C Frimas
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

4.  Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease.

Authors:  H H Kramer; M Sommer; S Rammos; O Krogmann
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

5.  Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial.

Authors:  J W Holcroft; M J Vassar; C J Weber
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

6.  Reversibility of cortical hyperostosis following long-term prostaglandin E1 therapy in infants with ductus-dependent congenital heart disease.

Authors:  A Høst; S Halken; P E Andersen
Journal:  Pediatr Radiol       Date:  1988

7.  Aneurysmal change of the ductus arteriosus after prostaglandin E1 administration for pulmonary atresia: demonstration with magnetic resonance imaging.

Authors:  S Tsubata; I Hashimoto; F Ichida; A Miyazaki; T Okada; A Murakami; H Morita; K Fukahara
Journal:  Pediatr Cardiol       Date:  1994 Jan-Feb       Impact factor: 1.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.